Patents by Inventor Roy A. Jensen

Roy A. Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6052460
    Abstract: In a skills-based ACD, an agent is selected to handle a call based on which available agent's handling of the call will produce the least deviation from the agent's target performance criteria, and a call is selected for handling by an agent based on which available call's handling will produce the least deviation from the agent's target performance criteria. Illustrative target performance criteria include target per-agent per-skill skill work time to staff time ratios. Moreover, the selected call is left waiting and the selected agent is left idle if handling of the call by the agent would increase deviation from the agent's target performance criteria. This serves to equalize the levels of service given to small skills (those staffed with few agents) and large skills (those staffed with many agents).
    Type: Grant
    Filed: December 17, 1997
    Date of Patent: April 18, 2000
    Assignee: Lucent Technologies Inc.
    Inventors: Thomas S. Fisher, Roy A. Jensen, Martin I. Reiman
  • Patent number: 5891857
    Abstract: Genetic analysis of familial breast and ovarian cancer indicates that BRCA1 is a tumor suppressor gene. The BRCA1 gene encodes a 190 kDa protein with sequence homology and biochemical analogy to the granin family of proteins. Granins are secreted from endocrine cells via the regulated secretory pathway and are proteolytically cleaved to yield biologically active peptides. BRCA1 protein localizes to secretory vesicles, and was demonstrated to be secreted. Gene transfer of BRCA1 inhibits growth and tumorigenesis of breast and ovarian cancer cells, but not colon or lung cancer cells or fibroblasts, suggesting that BRCA1 encodes a tissue-specific growth inhibitor. Thus, BRCA1 is a secreted growth inhibitor and functions by a mechanism not previously described for tumor suppressor genes. The BRCA2 breast and ovarian cancer gene encodes a protein that also includes a granin region, indicating that the BRCA2 protein is also a secreted tumor suppressor.
    Type: Grant
    Filed: February 20, 1996
    Date of Patent: April 6, 1999
    Assignees: Vanderbilt University, University of Washington
    Inventors: Jeffrey T. Holt, Roy A. Jensen, Mary-Claire King, David L. Page, Csilla I. Szabo, Thomas L. Jetton, Cheryl L. Robinson-Benion, Marilyn E. Thompson
  • Patent number: 5863739
    Abstract: Potent neutralizing monoclonal antibodies to the human .alpha. PDGF receptor (.alpha. PDGFR) and fragments thereof are described. These monoclonal antibodies specifically bind to an epitope on .alpha. PDGFR, inhibits PDGF binding with PDGF, antagonizes PDGF, and does not bind .beta. PDGFR receptor. A hybridoma cell line producing such a monoclonal antibody, methods of in vivo imaging of a pathological conditions and methods of inhibiting the growth of a neoplasia expressing .alpha. PDGFR, which use these monoclonal antibodies are also described. In vitro assays for detecting the presence of .alpha. PDGFR and for evaluating the binding affinity of a test compound are also described.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 26, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: William J. LaRochelle, Jacalyn Pierce, Roy A. Jensen, Stuart A. Aaronson
  • Patent number: 5833986
    Abstract: Potent neutralizing monoclonal antibodies to the human .alpha. PDGF receptor (.alpha. PDGFR) and fragments thereof are described. These monoclonal antibodies specifically bind to an epitope on .alpha. PDGFR, inhibits PDGF binding with PDGF, antagonizes PDGF, and does not bind .beta. PDGFR receptor. A hybridoma cell line producing such a monoclonal antibody, methods of in vivo imaging of a pathological conditions and methods of inhibiting the growth of a neoplasia expressing .alpha. PDGFR, which use these monoclonal antibodies are also described. In vitro assays for detecting the presence of .alpha. PDGFR and for evaluating the binding affinity of a test compound are also described.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: November 10, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: William J. LaRochelle, Jacalyn Pierce, Roy A. Jensen, Stuart A. Aaronson
  • Patent number: 5828747
    Abstract: A call-distribution function (150) of an ACD system (101) improves the equity of distribution of calls to agents (106-108) by basing the distribution on the agents' individual occupancies. Illustratively, determining an agent's occupancy involves either determining (304) how many calls the agent has handled within a predetermined time interval, or determining (305) how much time of a predetermined time interval the agent has spent on handling of calls. The occupancy is periodically re-determined, and a next call is allocated to the presently least-occupied one of agents who are available to take the call, or to an agent to whose occupancy the allocation will be most beneficial, such as an available agent to whom allocation of the call will maximize convergence of actual and target occupancies.
    Type: Grant
    Filed: January 28, 1997
    Date of Patent: October 27, 1998
    Assignee: Lucent Technologies Inc.
    Inventors: Thomas S. Fisher, Andrew D. Flockhart, Roy A. Jensen, Joylee E. Kohler, Eugene P. Mathews, Edward L. Smelko
  • Patent number: 5677125
    Abstract: The present invention provides a method of detecting and diagnosing pre-invasive breast cancer by identifying differentially expressed genes in early, pre-invasive breast cancer tissue. Differentially expressed genes can be used as genetic markers to indicate the presence of pre-invasive cancerous tissues. Microscopically-directed tissue sampling techniques combined with differential display or differential screening of cDNA libraries are used to determine differential expression of genes in the early stages of breast cancer. Differential expression of genes in preinvasive breast cancer tissue is confirmed by RT-PCR, nuclease protection assays and in-situ hybridization of ductal carcinoma in situ tissue RNA and control tissue RNA.
    Type: Grant
    Filed: January 14, 1994
    Date of Patent: October 14, 1997
    Assignee: Vanderbilt University
    Inventors: Jeffrey T. Holt, Roy A. Jensen, David L. Page, Patrice S. Obermiller, Cheryl L. Robinson-Benion
  • Patent number: 5468468
    Abstract: Potent neutralizing monoclonal antibodies to the human .alpha. PDGF receptor (.alpha. PDGFR) and fragments thereof are described. These monoclonal antibodies specifically bind to an epitope on .alpha. PDGFR, inhibits PDGF binding with PDGF, antagonizes PDGF, and does not bind .beta. PDGFR receptor. A hybridoma cell line producing such a monoclonal antibody, methods of in vivo imaging of a pathological conditions and methods of inhibiting the growth of a neoplasia expressing .alpha. PDGFR, which use these monoclonal antibodies are also described. In vitro assays for detecting the presence of .alpha. PDGFR and for evaluating the binding affinity of a test compound are also described.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: November 21, 1995
    Assignee: The United States of America, as represented by the Secretary of the Department of Health & Human Services
    Inventors: William J. LaRochelle, Jacalyn Pierce, Roy A. Jensen, Stuart A. Aaronson
  • Patent number: 5187071
    Abstract: A novel means for identifying selective control agents for weeds, pests, and microbes is provided. Novel compositions for the selective control of weeds, pests, and microbes are also provided. The critical elements in the novel method of the invention relate to the systematic and specific identification of points of diversity which exist between the target organism and the host or other non-target organisms. More specifically the process involves identifying a difference which exists between the metabolic pathway of a microbial or plant target organism and a non-target host specie and then preparing a control agent which perturbs the metabolic pathway of the target without significantly perturbing the metabolic pathway of the host.
    Type: Grant
    Filed: July 15, 1988
    Date of Patent: February 16, 1993
    Inventors: Randy S. Fischer, Roy A. Jensen